Quintin Robinson, MD
Infectious Disease · Atlanta, GANPI 1760684658
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $164,640 of the $269,715 with a category attached, or 61.0%. Viiv Healthcare Company accounts for 60.8% of it on its own, with 24 other manufacturers making up the rest. Among infectious disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 843 payments — averaging $319.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$164K
- Gilead$88K
- Merck$12K
- Theratechnologies Inc.$2K
- GSK$902
- EMD Serono, Inc.$499
- plus $2K from 19 others
Across 9 payments — averaging $1283.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$12K
What the payments were for
- Consulting fees$61,50323%
- Speaking & faculty fees$164,64061%
- Travel & lodging$23,7889%
- Food & beverage$19,2937%
- Education$4040%
- Gifts$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 383 | $164,065 |
| Gilead | 219 | $88,408 |
| Merck | 65 | $11,924 |
| Theratechnologies Inc. | 21 | $1,973 |
| GSK | 11 | $902 |
| EMD Serono, Inc. | 40 | $499 |
| Johnson & Johnson | 40 | $454 |
| AbbVie | 12 | $260 |
| Novo Nordisk | 12 | $214 |
| Janssen Products, LP | 2 | $200 |
| Lilly USA, LLC | 9 | $185 |
| Astellas Pharma US Inc | 5 | $164 |
| Octapharma USA, Inc. | 1 | $92 |
| Verity Pharmaceuticals Inc. | 4 | $63 |
| Antares Pharma, Inc. | 3 | $55 |
| Napo Pharmaceuticals Inc | 3 | $49 |
| Exact Sciences | 3 | $43 |
| Abbott | 2 | $41 |
| Pfizer | 2 | $28 |
| Halozyme Inc | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $17 |
| CSL Behring | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$269,715 in reported general payments places this provider in the 95th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 171 | $819,577 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 120 | $456,934 |
| SerostimSomatropin | 23 | $391,062 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 76 | $311,690 |
| TivicayDolutegravir Sodium | 120 | $307,517 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 74 | $286,455 |
| DovatoDolutegravir Sodium/Lamivudine | 98 | $285,578 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 39 | $126,045 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 31 | $110,854 |
| PrezcobixDarunavir/Cobicistat | 38 | $100,095 |
| RukobiaFostemsavir Tromethamine | 11 | $87,165 |
| IsentressRaltegravir Potassium | 43 | $83,853 |
| JulucaDolutegravir/Rilpivirine | 16 | $58,305 |
| DescovyEmtricitabine/Tenofov Alafenam | 26 | $54,569 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 14 | $32,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Rukobia, Juluca | $164,065 | $1,050,255321 claims |
| Janssen Products, LPSymtuza | $200 | $819,577171 claims |
| GileadGenvoya, Biktarvy, Descovy | $88,408 | $797,958220 claims |
| EMD Serono, Inc.Serostim | $499 | $391,06223 claims |
| CSL BehringPrivigen | $16 | $126,04539 claims |
| MerckIsentress, Delstrigo | $11,924 | $116,73857 claims |
| Johnson & JohnsonPrezcobix | $454 | $100,09538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Atlanta
- Zandraetta Tims-CookAtlanta$848K
- Larry AndersonAtlanta$300K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Colleen KraftAtlanta$103K
- Walter OrensteinAtlanta$78K
- Nadine RouphaelAtlanta$66K
- Kimberly WorkowskiAtlanta$53K
- Bernard BransonAtlanta$36K
- Michelle JonesAtlanta$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.